ISRCTN66850051已完成不适用
A phase I randomised single-blinded single-centre study comparing doses of Plasmodium falciparum chimeric protein 2.9 (PfCP-2.9) recombinant vaccine adjuvanted with Montanide ISA 720 for safety and immunogenicity
World Health Organization (WHO) (Switzerland)0 个研究点目标入组 52 人开始时间: 2007年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Healthy adult volunteers ages 18 - 45 years.
排除标准
- •1. History of malaria: persons infected with malaria or with positive markers for antibodies to malaria parasite by Indirect Fluorescent Antibody (IFA) assay
- •2. History of ever traveling to or residing in a malaria endemic region or malaria exposure within last two years
研究者
相似试验
已完成
1 期
Study to test the safety and tolerability of a new drug (DNDI-0690) in healthy subjectsVisceral leishmaniasis, cutaneous leishmaniasisInfections and InfestationsISRCTN14683791Drugs for Neglected Diseases Initiative64
已完成
不适用
A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers.NL-OMON35929Ablynx NV76
招募中
2 期
A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin α10β1-selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers2024-518757-42-00Xintela AB6
已完成
1 期
A Phase 1, Safety and Pharmacokinetic Study of CSL312 in Healthy SubjectsHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersInflammatory and Immune System - Other inflammatory or immune system disordersHereditary AngioedemaACTRN12616001438448CSL Limited48
已完成
1 期
A study to investigate the safety, tolerability and activity of multiple ascending doses of DNDI-0690 in healthy volunteers including assessment of heart and kidney functioThe safety, tolerability and fluid exposure of a drug aimed to treat visceral and cutaneous leishmaniasis in healthy volunteersISRCTN30122193Drugs for Neglected Diseases Initiative45